Repeat injections of onabotulinumtoxinA (Botox) over the long term are showing value in patients with interstitial cystitis.
Washington-OnabotulinumtoxinA (Botox) injected into the bladder has been a promising treatment for interstitial cystitis, but one plagued by the problem of retention. At the 2009 AUA annual meeting, low doses and trigone-only injection showed potential for effectiveness with no retention. Now, repeat injections over the long term are showing value in these patients.
At this year's AUA annual meeting in Washington, Rui Pinto, MD, a physician at Hospital de São João, São João, Portugal, reported on repeat injections in patients with refractory bladder pain syndrome/IC over the course of 5 years.
With the patient under general anesthesia, Dr. Pinto injected onabotulinumtoxinA, 100 U, through a rigid cystoscope into 10 sites from the trigone to the bladder neck (10 U per site in 1 mL of saline). (OnabotulinumtoxinA, which was recently granted FDA approval for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition, is not FDA approved for treatment of bladder pain syndrome/IC.) Patients received ciprofloxacin (Cipro, Proquin XR), 500 mg, 12 hours before and 2 days after injection.
Improvements in pain, nocturia seen
The changes were significant and similar after each treatment.
"The main improvements were in pain and nocturia," Dr. Pinto noted.
Pain scores dropped from between 5 and 6 to between 2 and 3 each time. Urinary frequency, which was generally 15 to 16 times a day before treatment, dropped to about 10. O'Leary-Sant scores of about 25 to 29 dropped to the 15 to 16 range. Quality of life scores of 5 to 6 improved to about 2.
"Patients related that the main improvement in frequency was nocturia," noted Dr. Pinto.
The most notable adverse event was urinary tract infection, of which there were five, mainly with Escherichiacoli. There were no cases of voiding dysfunction, including retention.
"We can conclude that intratrigonal injection of 100 U onabotulinumtoxinA is a safe, effective, and reproducible treatment for refractory PBS/IC," Dr. Pinto said.
Co-author Francisco Cruz, MD is a consultant for Allergan.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.